Advaxis, Inc. (NASDAQ:ADXS) announced two abstracts were selected for presentation at the 32nd annual Society for Immunotherapy of Cancer (SITC) meeting.
Analyst defends ADXS’ new “astute” clinical development strategy to re-focus on leading product assets.
Advaxis, Inc. (NASDAQ:ADXS) and SELLAS Life Sciences Group announced that Advaxis has granted SELLAS a license to develop a novel cancer immunotherapy agent …
Advaxis, Inc. (NASDAQ:ADXS) issued its 2017 business outlook to provide an overview of anticipated events and key milestones for the coming year, as …
Advaxis, Inc. (NASDAQ:ADXS) announced that the company’s proprietary bacterial vector system, its Lm Technology™, was the focal point of a luncheon during the …
Advaxis, Inc. (NASDAQ:ADXS) announced topline results from the early closure of stage 2 of the Phase 2 GOG-0265 trial, conducted by the Gynecologic Oncology …
Advaxis, Inc. (NASDAQ:ADXS) announced the commencement of Part B of the KEYNOTE-046 clinical trial evaluating Advaxis’ Lmimmunotherapy candidate, ADXS-PSA, in combination with KEYTRUDA (pembrolizumab) …
Advaxis, Inc. (NASDAQ:ADXS) has received preliminary approval for a $2.
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, welcomed New Jersey Governor Christopher J.
Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that it has entered into a definitive securities purchase agreement with healthcare …